Biomarker testing guides endometrial cancer treatment and highlights gaps in second-line options after immunotherapy

The discussion highlighted that performing biomarker testing at diagnosis is now standard for endometrial cancer, helping decide between targeted therapies and immunotherapy.

The experts described a shift from relying solely on tumor histology to using molecular markers such as mismatch repair deficiency, p53 mutations, HER2 amplification, and hormone-receptor status to guide treatment choices.

Consistent immunohistochemistry testing across all patients was emphasized as a way to prevent testing gaps and treatment delays, according to the panelists.

Despite improved front-line options, the panel noted a lack of effective second-line therapies for patients whose disease progresses after immunotherapy, underscoring an unmet clinical need.